Mylan’s abbreviated new drug application for morphine sulphate extended-release tablets has been approved by the US Food and Drug Administration (FDA) .
The tablets are available in doses of 15mg, 30mg, 60mg, 100mg and 200mg.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The dose formulations are the generic equivalent to Purdue Pharma’s MS Contin, an opioid analgesic for moderate-to-severe pain management.
